Syndax Pharmaceuticals, Inc. (SNDX)
9.54
+0.17
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
9.79
+0.25
(+2.62%)
After-Hours: 20:00
Syndax Pharmaceuticals EPS Diluted (Quarterly) : -0.5505 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.5505 |
| June 30, 2026 | -0.5547 |
| March 31, 2026 | -0.4835 |
| December 31, 2025 | -0.7786 |
| September 30, 2025 | -0.7009 |
| June 30, 2025 | -0.8322 |
| March 31, 2025 | -0.9846 |
| December 31, 2024 | -1.098 |
| September 30, 2024 | -0.9847 |
| June 30, 2024 | -0.7982 |
| March 31, 2024 | -0.8496 |
| December 31, 2023 | -0.9993 |
| September 30, 2023 | -0.7322 |
| June 30, 2023 | -0.6407 |
| March 31, 2023 | -0.5923 |
| December 31, 2022 | -0.6202 |
| September 30, 2022 | -0.5835 |
| June 30, 2022 | -0.6246 |
| March 31, 2022 | -0.6302 |
| December 31, 2021 | 1.844 |
| September 30, 2021 | -0.3972 |
| June 30, 2021 | -0.444 |
| March 31, 2021 | -0.5383 |
| December 31, 2020 | -0.4434 |
| September 30, 2020 | -0.4628 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.4202 |
| March 31, 2020 | -0.5576 |
| December 31, 2019 | -0.4425 |
| September 30, 2019 | -0.4056 |
| June 30, 2019 | -0.472 |
| March 31, 2019 | -0.5292 |
| December 31, 2018 | -0.7028 |
| September 30, 2018 | -0.6807 |
| June 30, 2018 | -0.74 |
| March 31, 2018 | -0.79 |
| December 31, 2017 | -0.80 |
| September 30, 2017 | -0.68 |
| June 30, 2017 | -0.70 |
| March 31, 2017 | -0.71 |
| December 31, 2016 | -0.59 |
| September 30, 2016 | -0.84 |
| June 30, 2016 | -0.47 |
| March 31, 2016 | -2.85 |
| September 30, 2014 | -149.63 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | -0.04 |
| December 31, 2013 | -0.03 |
| September 30, 2013 | 0.00 |
| March 31, 2013 | -0.03 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Emergent BioSolutions, Inc. | -0.6374 |
| Incyte Corp. | -3.861 |
| Vertex Pharmaceuticals, Inc. | 2.561 |
| Travere Therapeutics, Inc. | -0.645 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -49.43M |
| Revenue (Quarterly) | 83.30M |
| Total Expenses (Quarterly) | 132.73M |
| Enterprise Value | 1.021B |
| Gross Profit Margin (Quarterly) | 83.19% |
| Profit Margin (Quarterly) | -59.34% |
| Earnings Yield | -24.81% |
| Normalized Earnings Yield | -24.81 |